ReviewCurrent osteoporosis reports2024
Precision Renal Osteodystrophy: What's Race Got to do With It?
Review in Current osteoporosis reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewTo present race and ethnicity as evidence of the need for precision medicine in renal osteodystrophy. RECENT
findingsPreviously described racial-ethnic differences in bone persist in recent data on fracture risk in the healthy and CKD populations. These differences have historically been noted between Black and White participants, but recent data suggests racial-ethnic differences in bone are more intricate than previously recognized. A reflection on skeletal differences within the general, non-CKD population, provides a context to better understand skeletal differences by race within CKD. Despite numerous studies demonstrating racial differences in skeletal microarchitecture, fracture risk and skeletal biomarkers, further evidence is needed to pinpoint the etiology of racial differences and to allow precision treatment that reflects the individual patient, regardless of race. In the end, race is currently our most saliant example of the need for a precision medicine approach to the treatment of renal osteodystrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.